Literature DB >> 22311724

Tumor tropism of intravenously injected human-induced pluripotent stem cell-derived neural stem cells and their gene therapy application in a metastatic breast cancer model.

Jing Yang1, Dang Hoang Lam, Sally Sallee Goh, Esther Xingwei Lee, Ying Zhao, Felix Chang Tay, Can Chen, Shouhui Du, Ghayathri Balasundaram, Mohammad Shahbazi, Chee Kian Tham, Wai Hoe Ng, Han Chong Toh, Shu Wang.   

Abstract

Human pluripotent stem cells can serve as an accessible and reliable source for the generation of functional human cells for medical therapies. In this study, we used a conventional lentiviral transduction method to derive human-induced pluripotent stem (iPS) cells from primary human fibroblasts and then generated neural stem cells (NSCs) from the iPS cells. Using a dual-color whole-body imaging technology, we demonstrated that after tail vein injection, these human NSCs displayed a robust migratory capacity outside the central nervous system in both immunodeficient and immunocompetent mice and homed in on established orthotopic 4T1 mouse mammary tumors. To investigate whether the iPS cell-derived NSCs can be used as a cellular delivery vehicle for cancer gene therapy, the cells were transduced with a baculoviral vector containing the herpes simplex virus thymidine kinase suicide gene and injected through tail vein into 4T1 tumor-bearing mice. The transduced NSCs were effective in inhibiting the growth of the orthotopic 4T1 breast tumor and the metastatic spread of the cancer cells in the presence of ganciclovir, leading to prolonged survival of the tumor-bearing mice. The use of iPS cell-derived NSCs for cancer gene therapy bypasses the sensitive ethical issue surrounding the use of cells derived from human fetal tissues or human embryonic stem cells. This approach may also help to overcome problems associated with allogeneic transplantation of other types of human NSCs.
Copyright © 2012 AlphaMed Press.

Entities:  

Mesh:

Year:  2012        PMID: 22311724     DOI: 10.1002/stem.1051

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  26 in total

1.  Tumor-homing cytotoxic human induced neural stem cells for cancer therapy.

Authors:  Juli R Bagó; Onyi Okolie; Raluca Dumitru; Matthew G Ewend; Joel S Parker; Ryan Vander Werff; T Michael Underhill; Ralf S Schmid; C Ryan Miller; Shawn D Hingtgen
Journal:  Sci Transl Med       Date:  2017-02-01       Impact factor: 17.956

Review 2.  Engineering Stem Cells for Biomedical Applications.

Authors:  Perry T Yin; Edward Han; Ki-Bum Lee
Journal:  Adv Healthc Mater       Date:  2015-03-13       Impact factor: 9.933

Review 3.  Practical Issues with the Use of Stem Cells for Cancer Gene Therapy.

Authors:  Faranak Salman Nouri; Debabrata Banerjee; Arash Hatefi
Journal:  Stem Cell Rev Rep       Date:  2015-10       Impact factor: 5.739

4.  Genetically engineered theranostic mesenchymal stem cells for the evaluation of the anticancer efficacy of enzyme/prodrug systems.

Authors:  Faranak Salman Nouri; Xing Wang; Arash Hatefi
Journal:  J Control Release       Date:  2015-01-07       Impact factor: 9.776

5.  Frontiers in Suicide Gene Therapy of Cancer.

Authors:  Marek Malecki
Journal:  J Genet Syndr Gene Ther       Date:  2012-10-22

Review 6.  Stem cell-based therapies for cancer treatment: separating hope from hype.

Authors:  Daniel W Stuckey; Khalid Shah
Journal:  Nat Rev Cancer       Date:  2014-09-01       Impact factor: 60.716

7.  Stem Cells Engineered During Different Stages of Reprogramming Reveal Varying Therapeutic Efficacies.

Authors:  Deepak Bhere; Rajiv Kumar Khajuria; William T Hendriks; Antara Bandyopadhyay; Tugba Bagci-Onder; Khalid Shah
Journal:  Stem Cells       Date:  2018-04-01       Impact factor: 6.277

8.  Zinc finger nuclease-expressing baculoviral vectors mediate targeted genome integration of reprogramming factor genes to facilitate the generation of human induced pluripotent stem cells.

Authors:  Rui-Zhe Phang; Felix Chang Tay; Sal-Lee Goh; Cia-Hin Lau; Haibao Zhu; Wee-Kiat Tan; Qingle Liang; Can Chen; Shouhui Du; Zhendong Li; Johan Chin-Kang Tay; Chunxiao Wu; Jieming Zeng; Weimin Fan; Han Chong Toh; Shu Wang
Journal:  Stem Cells Transl Med       Date:  2013-10-28       Impact factor: 6.940

9.  Systemic delivery of fusogenic membrane glycoprotein-expressing neural stem cells to selectively kill tumor cells.

Authors:  Detu Zhu; Dang Hoang Lam; Yovita Ida Purwanti; Sal Lee Goh; Chunxiao Wu; Jieming Zeng; Weimin Fan; Shu Wang
Journal:  Mol Ther       Date:  2013-06-11       Impact factor: 11.454

10.  Antitumor effects of CD40 ligand-expressing endothelial progenitor cells derived from human induced pluripotent stem cells in a metastatic breast cancer model.

Authors:  Yovita Ida Purwanti; Can Chen; Dang Hoang Lam; Chunxiao Wu; Jieming Zeng; Weimin Fan; Shu Wang
Journal:  Stem Cells Transl Med       Date:  2014-06-27       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.